HUTCHMED CHINA-ADR (HCM) Stock Fundamental Analysis
USA - NASDAQ:HCM - US44842L1035 - ADR
15.43 USD
+0.75 (+5.11%)
HCM gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of HCM get a neutral evaluation. Nothing too spectacular is happening here. HCM is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!
1. Profitability
1.1 Basic Checks
In the past year HCM was profitable.
In the past year HCM has reported a negative cash flow from operations.
In multiple years HCM reported negative net income over the last 5 years.
In multiple years HCM reported negative operating cash flow during the last 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 26.29%, HCM belongs to the top of the industry, outperforming 98.44% of the companies in the same industry.
With an excellent Return On Equity value of 37.99%, HCM belongs to the best of the industry, outperforming 96.88% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 26.29% | ||
| ROE | 37.99% | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 77.53%, HCM belongs to the best of the industry, outperforming 99.48% of the companies in the same industry.
HCM has a better Gross Margin (44.15%) than 62.50% of its industry peers.
In the last couple of years the Gross Margin of HCM has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 77.53% | ||
| GM | 44.15% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y17.54%
GM growth 5Y15.38%
2. Health
2.1 Basic Checks
HCM does not have a ROIC to compare to the WACC, probably because it is not profitable.
HCM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 3.62 indicates that HCM is not in any danger for bankruptcy at the moment.
HCM has a Altman-Z score of 3.62. This is in the better half of the industry: HCM outperforms 71.88% of its industry peers.
HCM has a Debt/Equity ratio of 0.08. This is a healthy value indicating a solid balance between debt and equity.
HCM has a Debt to Equity ratio (0.08) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.08 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.62 |
ROIC/WACCN/A
WACC8.87%
2.3 Liquidity
A Current Ratio of 4.65 indicates that HCM has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 4.65, HCM is in the better half of the industry, outperforming 67.19% of the companies in the same industry.
A Quick Ratio of 4.51 indicates that HCM has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 4.51, HCM is in the better half of the industry, outperforming 67.19% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.65 | ||
| Quick Ratio | 4.51 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 1172.34% over the past year.
HCM shows a decrease in Revenue. In the last year, the revenue decreased by -1.41%.
The Revenue has been growing by 25.20% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)1172.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1661.49%
Revenue 1Y (TTM)-1.41%
Revenue growth 3Y20.96%
Revenue growth 5Y25.2%
Sales Q2Q%-9.16%
3.2 Future
HCM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 52.63% yearly.
The Revenue is expected to grow by 20.25% on average over the next years. This is a very strong growth
EPS Next Y897.09%
EPS Next 2Y86.15%
EPS Next 3Y60.79%
EPS Next 5Y52.63%
Revenue Next Year-11.78%
Revenue Next 2Y0.94%
Revenue Next 3Y6.11%
Revenue Next 5Y20.25%
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 5.67, which indicates a rather cheap valuation of HCM.
Based on the Price/Earnings ratio, HCM is valued cheaply inside the industry as 96.35% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 26.11. HCM is valued rather cheaply when compared to this.
A Price/Forward Earnings ratio of 32.53 indicates a quite expensive valuation of HCM.
Based on the Price/Forward Earnings ratio, HCM is valued a bit cheaper than 72.40% of the companies in the same industry.
HCM is valuated rather expensively when we compare the Price/Forward Earnings ratio to 22.55, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.67 | ||
| Fwd PE | 32.53 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as HCM's earnings are expected to grow with 60.79% in the coming years.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y86.15%
EPS Next 3Y60.79%
5. Dividend
5.1 Amount
HCM does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:HCM (11/3/2025, 2:47:12 PM)
15.43
+0.75 (+5.11%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners21.97%
Inst Owner Change0%
Ins Owners0.58%
Ins Owner ChangeN/A
Market Cap2.65B
Revenue(TTM)602.20M
Net Income(TTM)466.88M
Analysts83.7
Price Target16.25 (5.31%)
Short Float %0.37%
Short Ratio7.31
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-6.59%
PT rev (3m)-10.18%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)8.62%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-15.55%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.67 | ||
| Fwd PE | 32.53 | ||
| P/S | 4.4 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.16 | ||
| P/tB | 2.16 | ||
| EV/EBITDA | N/A |
EPS(TTM)2.72
EY17.63%
EPS(NY)0.47
Fwd EY3.07%
FCF(TTM)-0.35
FCFYN/A
OCF(TTM)-0.19
OCFYN/A
SpS3.5
BVpS7.15
TBVpS7.15
PEG (NY)0.01
PEG (5Y)N/A
Graham Number20.92
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 26.29% | ||
| ROE | 37.99% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 77.53% | ||
| GM | 44.15% | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y17.54%
GM growth 5Y15.38%
F-Score5
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.08 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 221.94% | ||
| Cap/Sales | 4.5% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.65 | ||
| Quick Ratio | 4.51 | ||
| Altman-Z | 3.62 |
F-Score5
WACC8.87%
ROIC/WACCN/A
Cap/Depr(3y)321.95%
Cap/Depr(5y)304.39%
Cap/Sales(3y)5.11%
Cap/Sales(5y)5.73%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1172.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1661.49%
EPS Next Y897.09%
EPS Next 2Y86.15%
EPS Next 3Y60.79%
EPS Next 5Y52.63%
Revenue 1Y (TTM)-1.41%
Revenue growth 3Y20.96%
Revenue growth 5Y25.2%
Sales Q2Q%-9.16%
Revenue Next Year-11.78%
Revenue Next 2Y0.94%
Revenue Next 3Y6.11%
Revenue Next 5Y20.25%
EBIT growth 1Y83.69%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year98.89%
EBIT Next 3Y51.23%
EBIT Next 5Y43.18%
FCF growth 1Y-2591.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-168.32%
OCF growth 3YN/A
OCF growth 5YN/A
HUTCHMED CHINA-ADR / HCM FAQ
Can you provide the ChartMill fundamental rating for HUTCHMED CHINA-ADR?
ChartMill assigns a fundamental rating of 5 / 10 to HCM.
What is the valuation status of HUTCHMED CHINA-ADR (HCM) stock?
ChartMill assigns a valuation rating of 5 / 10 to HUTCHMED CHINA-ADR (HCM). This can be considered as Fairly Valued.
Can you provide the profitability details for HUTCHMED CHINA-ADR?
HUTCHMED CHINA-ADR (HCM) has a profitability rating of 4 / 10.
Can you provide the financial health for HCM stock?
The financial health rating of HUTCHMED CHINA-ADR (HCM) is 5 / 10.